MedPath

Cardiovascular Disease (CVD) Risk Assessment and Lipid Lowering Treatment in Type 2 Diabetes Mellitus Patients Treated at Secondary and/or Tertiary Hospitals in Korea

Not Applicable
Conditions
Endocrine, nutritional and metabolic disease
Registration Number
KCT0004984
Lead Sponsor
Pfizer Upjohn Korea
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot yet recruiting
Sex
All
Target Recruitment
2000
Inclusion Criteria

1. Adult Type 2 diabetes mellitus patients (=20 years) treated at secondary and/or tertiary hospitals
2. Patients with a record on cholesterol level at the time of enrollment

Exclusion Criteria

1. Patients currently participating in other drug-controlled interventional study
2. Patients in severe or unstable medical conditions by physicians’ discretion during the recruitment

Study & Design

Study Type
Observational Study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
the risks of cardiovascular diseases;lipid lowering treatments;the concordance with clinical practice guidelines
Secondary Outcome Measures
NameTimeMethod
the lipid lowering treatment modifications
© Copyright 2025. All Rights Reserved by MedPath